TherapeuticsMD, Inc. (TXMD) Q1 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen. Thank you for joining us for TherapeuticsMD's first quarter 2022 financial results conference call. I will now turn the call over to Investor Relations for TherapeuticMD's Lisa Wilson. You may begin. Thank you, Operator. Good afternoon, everyone. and thank you for joining today to discuss our first quarter financial results and business update. This afternoon, TherapeuticsMD issued a press release announcing its first quarter 2022 financial results. The press release and accompanying presentation are available on the company's website, TherapeuticsMD, in the Investors and Media section. On today's call from TherapeuticsMD are Chief Executive Officer Hugh O'Dowd, Interim Chief Financial Officer Michael Donegan, and Chief Commercial Officer Mark Glickman. I would like to remind everyone that certain statements made during this conference call may be forward-looking statements. Such forward-looking statements are based upon current expectations and there can be no assurance that the results contemplated in these statements will be realized. Actual results may differ materially from such statements due to a number of factors of risks, some of which are identified in our press release, and are annual, quarterly, and other reports filed with the SEC. These forward-looking statements are based upon information available to TherapeuticsMD today and the company assumes no obligation to update these statements as circumstances change. An audio recording and webcast replay for today's conference call will also be available online in the Investors and Media section of the company's website. For the benefit of those who may be listening to the replay or archived webcast, this call was held and recorded on May 16, 2022. With that, I'll turn th...